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Abstract 
Background: Prostate-specific antigen(PSA) and PSA-velocity(PSAV) have been used to 
identify men at risk of prostate cancer(PrCa). The IMPACT study is evaluating PSA screening 
in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis 
evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this 
cohort. 
Methods: PSAV was calculated using logistic regression to determine if PSA or PSAV 
predicted the result of prostate biopsy(PB) in men with elevated PSA values. Cox regression 
was used to determine whether PSA or PSAV predicted PSA elevation in men with low PSAs. 
Interaction terms were included in the models to determine whether BRCA status 
influenced the predictiveness of PSA or PSAV. 
Results: 1634 participants had >3 PSA readings of whom 174 underwent PB and 45 PrCas 
diagnosed. In men with PSA >3.0ng/ml, PSAV was not significantly associated with presence 
of cancer or high-grade disease. PSAV did not add to PSA for predicting time to an elevated 
PSA. When comparing BRCA1/2 carriers to non-carriers, we found a significant interaction 
between BRCA status and last PSA before biopsy(p=0.031) and BRCA2 status and 
PSAV(p=0.024). However, PSAV was not predictive of biopsy outcome in BRCA2 carriers. 
Conclusions: PSA is more strongly predictive of PrCa in BRCA carriers than non-carriers. We 
did not find evidence that PSAV aids decision-making for BRCA carriers over absolute PSA 
value alone. 
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Introduction 
Men with germline mutations in BRCA2 have an increased risk of prostate cancer (PrCa), 
estimated at 2.5-8.6 fold increased risk for BRCA2 mutation carriers (BCLC, 1999; Kote-Jarai 
et al, 2011; van Asperen et al, 2005). There remains debate about whether there is an 
increased risk of PrCa associated with BRCA1 mutations, with some studies reporting no 
increased risk to those reporting a 1.8-3.75 fold increased risk (Leongamornlert et al, 2012; 
Moran et al 2012; Thompson et al, 2002). A number of studies have reported that BRCA2 
mutation carriers have more aggressive disease, suggested by their younger age at 
diagnosis, higher rates of lymph node involvement and distant metastasis at diagnosis, and 
higher mortality rates compared with non-carriers (Castro et al, 2013; Edwards et al, 2010; 
Gallagher et al, 2010; Mitra et al, 2008; Thorne et al, 2011; Trygvadottir et al, 2007). There is 
increasing evidence that BRCA1 mutation carriers may also harbour more aggressive disease 
(Castro et al, 2013; Gallagher et al, 2010; Giusti et al, 2003). Furthermore, BRCA2-mutant 
localised prostate cancer demonstrates increased genomic instability and a mutational 
profile that more closely resembles metastastic than localised disease, therefore supporting 
early detection in this at risk patient population (Taylor et al, 2017).  
General population prostate specific antigen (PSA) screening remains controversial due to 
an unclear balance of benefits, in terms of mortality reduction when compared to harms 
such as overdiagnosis and overtreatment. However, many expert groups continue to 
recommend PrCa screening with particular attention towards men with risk factors based 
on family history, genetics and/or race (Roobol et al, 2013; Mikropoulos et al, 2014; Eeles et 
al, 2014; Murphy et al 2014).  
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It has previously been suggested that the rate of PSA change over time, or PSA velocity 
(PSAV), can be used to assist in differentiating between men with cancer from those with 
benign disease (Carter et al, 1992; Berger et al, 2005). Monitoring PSA over time could also 
improve the sensitivity of screening. It is also possible that PSAV could distinguish between 
men who might have advanced or aggressive disease that would require definitive 
treatment thus avoiding overdiagnosis and overtreatment. 
However, the utility of PSAV in PrCa decision-making has been called into question. In 
particular, while PSAV may be predictive of biopsy outcome in univariate analyses, it has not 
been shown to improve the predictiveness of biopsy outcome over the absolute value of 
PSA (Loughlin, 2014; Roobol et al, 2004; Vickers et al, 2011). Although some studies have 
suggested that PSAV can be used to identify men with aggressive disease, these did not 
investigate whether calculation of PSAV provided additional information than the most 
recent PSA value (Carter et al, 1992; D’Amico et al, 2005; D’Amico et al, 2004). PSA and 
PSAV are highly correlated, and this may explain why PSAV does not add predictive value 
(Vickers et al, 2011). As a result of these considerations, PSAV has been removed from all 
major guidelines concerning the detection of prostate cancer. 
It is currently unknown whether PSAV provides more information, beyond PSA absolute 
value, among a cohort of men considered to be at increased genetic risk of PrCa and 
aggressive disease. The IMPACT study (Identification of Men with a genetic predisposition to 
ProstAte Cancer: Targeted screening in men at higher genetic risk and controls; 
www.impact-study.co.uk) is an international multi-centre study evaluating the role of 
targeted PSA screening in men with a BRCA1 or BRCA2 mutation and was established in 
2005 (Bancroft et al, 2014). To date, approximately 3000 men have been recruited from 20 
PSA Velocity in IMPACT Study 
12 
 
countries across the world. Men are followed up with annual (or biannual in the Dutch 
cohort) PSA screening for a minimum of 5 years within the study and this has produced a 
wealth of PSA results and follow-up data over time. The primary end-point of the IMPACT 
study is to determine the incidence, stage and pathology of screen-detected prostate cancer 
in the study population; a secondary end-point is to determine a profile of PSA level and its 
predictive value for the development of prostate cancer in the study population. The 
objective of the present study was to determine whether PSA values and/or PSAV were 
associated with PrCa and aggressive tumours among men at increased risk enrolled in the 
IMPACT trial. 
 
Materials and Methods 
Patient Selection 
The design and eligibility criteria for the IMPACT study have been described elsewhere 
(Mitra et al, 2008; Bancroft et al, 2014). The protocol was approved by the West-Midlands 
Research and Ethics Committee in the UK (reference 05/MRE07/25), and subsequently by 
each participating institution’s local committee. Briefly, men aged between 40 and 69 were 
recruited from families with a known pathogenic germline BRCA1 or BRCA2 mutation. Men 
were invited to enrol if they had tested positive (carriers) or negative for the familial 
mutation (BRCA1/2 non-carriers), or if they were at 50% risk of inheriting a mutation but 
had not yet undergone predictive genetic testing. All participants provide written consent. 
Men with PrCa or with a prior diagnosis of another cancer with a prognosis of <5 years were 
PSA Velocity in IMPACT Study 
13 
 
excluded. In the Dutch centres, men were also excluded if they had PSA screening prior to 
study entry. 
According to the IMPACT study design, men underwent annual PSA screening and those 
with a PSA >3.0ng/ml were referred for a ten- or twelve-core transrectal ultrasound guided 
(TRUS) biopsy based on institutional clinic practices. Men with a PSA >3.0ng/ml and a 
negative biopsy continue annual screening, with a repeat biopsy recommended when PSA 
increased by >50%. Men were also referred for biopsy if they had a PSA <3.0ng/ml but 
clinical suspicion (e.g. abnormal digital rectal examination or clinical symptoms). After five 
years in the study, men at a subset of centres were also offered an elective biopsy. 
PSA readings in the study are validated in a central laboratory to exclude inter-site 
variations. The results found a Spearman’s agreement of 0.95 between study sites (Bancroft 
et al, 2014). 
 
Figure 1: Consort diagram of study population.  The two bolded cohorts were included for 
in-depth analysis, as they had 3 or more PSA values available for analysis and underwent a 
prostate biopsy. 
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Statistical considerations 
PSA velocity (PSAV) has been used as a marker to inform decisions about biopsy or about 
the timing of the next PSA screen. With respect to the former, we considered that a 
physician had the most recent PSA measurements available. Our study question was 
therefore whether adding PSAV to this data point improves prediction of presence of PrCa 
at biopsy. As elevated PSA is the primary indication in routine clinical practice, our main 
analysis was restricted to men who had any PSA >3.0ng/ml prior to biopsy. A sensitivity 
analysis was conducted including all men who underwent biopsy. We created logistic 
regression models, adjusted for last PSA measurement and age, for the outcomes of any 
grade and high-grade cancer. PSAV was calculated using three methods: arithmetic equation 
of change in PSA over time; linear regression; rate of PSA change using first and last values 
only. We also used cubic splines with knots at the tertiles to test for non-linearity in PSA and 
in PSAV. 
To investigate whether the effect of PSAV on predicting biopsy outcome differed based on 
BRCA status, we included an interaction term between PSAV and BRCA status (BRCA1 or 
BRCA2 carriers vs BRCA non-carrier patients, and BRCA2 carriers vs BRCA1 and BRCA non-
carrier patients). Due to a limited number of events, this analysis was performed only for 
the outcome of any cancer on biopsy. This analysis included 13 cancers diagnosed among 55 
BRCA1 carriers and 23 cancers among 65 BRCA2 carriers. 
To determine whether PSAV could aid decisions about screening frequency, e.g. whether a 
man with a high PSAV should receive a subsequent PSA test at a shorter interval than a man 
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with low PSAV, we assessed whether PSAV was associated with having a future PSA 
>3.0ng/ml. As a minimum of three PSA measurements are required for accurate estimation 
of PSAV, we created Cox proportional hazards models for the time from the first PSA 
measurement to the patient’s third PSA measurement >3.0ng/ml. Four models were then 
created: one including the third PSA measurement only, and the others including both the 
third PSA measurement and each of the three methodologies for calculating PSAV. Men 
who had a PSA >3.0ng/ml within the first three PSA measurements were excluded from this 
analysis. A total of 1086 men were included. 
We planned to first evaluate the independent statistical significance of PSAV in models that 
also included absolute PSA level. If significant, we planned to estimate the improvement in 
concordance index afforded by PSAV after 10-fold cross-validation. All analyses were 
conducted using Stata 13.0 (Stata Corp., College Station, Texas). 
 
 
Results 
Of the 2942 men recruited to the IMPACT study, 1654 men had three or more PSA 
measurements and appropriate clinical follow-up to be included in the analyses (Figure 1). 
Table 1 shows the demographic, PSA and biopsy grade characteristics of the analysis 
cohorts. The cohort of 1654 men consisted of 510 BRCA1 mutation carriers, 584 BRCA2 
mutation carriers, 260 BRCA1 non-carriers and 288 BRCA2 non-carriers. Two men carried 
both a BRCA1 and BRCA2 mutation (included in the BRCA2 group for genetic sub-analysis) 
and 10 had not yet had a predictive test for the BRCA mutation in their family (excluded 
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from genetic sub-analysis). In this cohort, 174 men underwent prostate biopsy, with 45 men 
having any grade cancer of whom 21 having Gleason score 7 or higher (high-grade) cancer. 
Among men who had any PSA >3.0ng/ml, 40 had any grade of whom 20 had high-grade 
cancer. 
The median age at the first PSA of BRCA2 carriers was significantly younger than both BRCA1 
carriers and non-carriers (51 vs. 53 vs. 54 years, respectively, p<0.0001). Overall, BRCA2 and 
BRCA1 carriers had significantly lower first PSA values than non-carriers (0.80 vs. 0.80 vs. 
0.89ng/ml; p=0.022; however, overall there was no statistically significant difference in the 
median PSAV between the BRCA2, BRCA1 and non-carrier groups (p = 0.8). 
The median age at first PSA reading of men diagnosed with cancer was higher than that of 
men without cancer (60 vs 53 years, U = 22069, z = -5.24, p<0.001). The median most recent 
PSA (i.e. PSA at diagnosis for cancer cases) was significantly higher for those with cancer 
compared with those without cancer (3.70 vs 0.90 ng/ml) U = 8564, z = -9.34, p<0.001). The 
median PSAV was significantly higher for those with cancer versus those without cancer 
(medians: 0.56 vs 0.02 ng/ml/yr, U = 9641, z = -9.012, p<0.001). Of those diagnosed with 
cancer, there was no significant difference between the proportion of BRCA2 carriers with a 
PSAV (calculated by linear regression) >0.35ng/ml/yr compared with BRCA1 carriers and 
non-carrier controls (78.3 vs 61.5 vs 53.8%, p0.28). 
We next assessed whether adding PSAV to the most recent PSA measurement would 
improve the ability to determine which men should undergo biopsy. Using cubic splines, we 
investigated and found no evidence of non-linearity in PSA or in PSAV. Among men with any 
PSA measurements >3.0ng/ml, PSAV was not significantly associated with either any grade 
or high-grade cancer after adjusting for most recent PSA measurement (Table 2). We 
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repeated these analyses including all men who were biopsied, and found that PSAV was not 
statistically significant in any of the models (Table 3). 
Additionally, we assessed whether PSAV affected the prediction of PrCa at biopsy differently 
based on BRCA status. When comparing BRCA1 and BRCA2 carriers to BRCA1/2 non-carriers, 
we found a significant interaction between BRCA status and the last PSA before biopsy 
(p=0.031), however there was no evidence of an interaction between BRCA status and PSAV 
(Table 4). However, when comparing BRCA2 carriers to BRCA1 carriers and BRCA1/2 non-
carriers, we found evidence of interactions between BRCA2 status and last PSA before 
biopsy (p=0.078) and significant interactions between BRCA2 status and PSAV calculated 
using the arithmetic equation and linear regression (p=0.024 and p=0.049 respectively, 
Table 4). 
Based on these interactions, we performed subgroup analyses by BRCA2 status. All models 
were adjusted for age at biopsy and last PSA before biopsy. Due to a limited number of 
events (26 cancers in BRCA2 non-carriers and 23 in BRCA2 carriers), these models were 
somewhat overfit. No evidence of an association between PSA and any grade cancer or 
PSAV and any grade cancer was seen in BRCA2 carriers or non-carriers, likely due to the 
strong correlation between PSA and PSAV (Table 5). 
We then investigated whether PSAV was associated with time to PSA ≥3.0ng/ml. Using Cox 
proportional hazards models, we found no evidence of an association between PSAV and 
time from the third PSA measurement to PSA ≥3.0ng/ml. Out of 1533 men who did not have 
a PSA ≥3.0ng/ml within the first three PSA tests, there were 28 who had a PSA ≥3.0ng/ml 
within 1 year, 50 within 2 years and 62 within 3 years. 
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Discussion 
This is the first study to show that there are differences in PSA values among men with 
different genetic backgrounds.  These PSA differences could be used to identify those men 
considered to be at high genetic risk of more aggressive disease. However, when evaluated 
with absolute PSA values, PSAV did not appear to provide additional information for BRCA1 
or BRCA2 carriers. 
A major problem of PSA screening is that, in attempting to detect clinically significant 
disease, it is inevitable that indolent disease will also be detected leading to overdiagnosis. 
However, early diagnosis and identification of men with high-risk disease is important to 
prevent mortality from PrCa. This might be particularly essential in light of recent 
publications indicating that men with a BRCA1 or BRCA2 mutation are at risk of more 
aggressive disease (Castro et al, 2013; Castro et al, 2015), early identification of those with 
clinically significant disease will be imperative. In view of the controversy about the role of 
PSAV in prostate screening in the general population, it was important to assess its role in 
BRCA1 and BRCA2 carriers and whether it added to the ability to detect clinically significant 
disease. 
In this analysis of the IMPACT study cohort, we found BRCA2 carriers on average to be 
screened at a relatively young age. This may account for lower overall PSA values for BRCA2 
carriers in this analysis compared to non-carrier controls. However, there were no 
differences in median PSAV between carriers and non-carriers. Given the possibility that 
higher PSAV may associate with aggressive PrCa (D’Amico et al, 2005; D’Amico et al, 2004), 
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we would expect BRCA2 carriers who are at risk of aggressive disease would exhibit higher 
PSAVs (Castro et al, 2013; Castro et al, 2015). BRCA2 carriers in this group may be too young 
to demonstrate this trend at this point of follow up. 
A single PSA reading over 3ng/ml was applied to guide biopsy decisions according to the 
IMPACT protocol, as well as if there was clinical suspicion on digital rectal examination or 
clinical symptoms. PSAV was not a good indicator in this analysis for distinguishing between 
those with any grade cancer and high-grade cancer when men were biopsied for either 
indication. It is possible that PSAV could be a good predictor of high-grade disease in men 
who had PSA values ≤2ng/ml (Kitagawa et al, 2014). However, due to the protocol’s 3ng/ml 
PSA threshold for prostate biopsy, we were limited in the number of cancers diagnosed 
when PSA was ≤2ng/ml. Further follow up will be required to assess when additional 
cancers are diagnosed. As part of the IMPACT trial, there is an optional end of study biopsy 
regardless of PSA. This may help delineate PSAV among men diagnosed with PrCa with low 
PSA values (Kitagawa et al, 2014; Carter et al, 1992). 
A strength of this study is the unique patient cohort of men with a genetic predisposition to 
PrCa, in particular BRCA2 carriers who are predisposed to aggressive PrCas (Castro et al, 
2013; Mitra et al, 2008; Castro et al, 2015; Narod et al, 2008). Within the group of BRCA2 
carriers, PSAV proved predictive of any grade cancer, however given the low number of 
cancers diagnosed overall it was not possible to assess whether PSAV was associated with 
high grade cancer and BRCA2 status. A high PSAV in an individual with a BRCA2 mutation 
could be used as an indicator of presence of PrCa and therefore as an indication for prostate 
biopsy. This model could lead to diagnosis of lower grade cancers in BRCA2 carriers. It may 
lead to better prognosis for men at risk for more aggressive disease and better disease free 
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survival when treated early. Although there are no definitive treatment recommendations 
for men with BRCA2 mutations when found to be diagnosed with low grade cancers, their 
risk for aggressive disease may spur them to follow a more active treatment plan such as 
radical prostatectomy versus external-beam radiation therapy or active surveillance (Castro 
et al, 2015; Bratt and Loman, 2015). 
One major limitation of this analysis is the relatively small number of men in the study who 
had undergone diagnostic prostate biopsy. End of study biopsies are not mandated and the 
true incidence of PrCa is unknown in this population. As more men progress through the 
IMPACT screening study, undergo prostate biopsy and follow-up time increases, the findings 
from this analysis can be explored and validated. At this point, the results from this analysis 
did not justify modifying the study algorithm to include a PSAV calculation. 
In the general population, PSAV is not part of any major screening guideline. We also did not 
find PSAV to be an independent prognostic factor in BRCA1 or BRCA2 mutation carriers and 
therefore for screening an absolute PSA cut-off value should preferably be used. 
 
Conclusion 
PSA is more strongly predictive of PrCa in BRCA carriers than BRCA non-carriers. We did not 
find evidence that PSAV aids to decision making for either indicating biopsy or frequency of 
follow-up testing in BRCA carriers, but further follow-up is required for more definitive 
conclusions. 
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Table 1. Patient characteristics. Data are reported as median (interquartile range) or frequency (%). 
 Total cohort 
N=1654 
BRCA2 
N=586*  
BRCA1 
N=510 
Non-Carrier 
Controls (BRCA1 
and BRCA2 
negative) N=548 
Age at first PSA test 53 (46, 60) 51 (45, 59) 53 (46, 60) 54 (48, 61) 
Patient underwent 
biopsy 
174 (11%) 65 (11%) 55 (11%) 54 (10%) 
Prior negative biopsy 26 (1.6%) 8 (1.4%) 8 (1.6%) 10 (1.8%) 
Biopsy Gleason score     
    <=6 24 (14%) 11 (17%) 6 (11%) 7 (13%) 
    7 15 (8.6%) 6 (9.2%) 6 (11%) 3 (5.6%) 
    >7 6 (3.4%) 5 (7.7%) 0 (0%) 1 (1.9%) 
    Negative biopsy 129 (74%) 43 (66%) 43 (78%) 43 (80%) 
First PSA measurement 
(ng/ml) 
0.8 (0.5, 1.3) 0.80 (0.50, 1.20) 0.80 (0.50, 
1.30) 
0.89 (0.60, 1.40) 
Last PSA measurement 
(ng/ml) 
0.9 (0.6, 1.6) 0.91 (0.59, 1.50) 0.88 (0.55, 
1.70) 
1.00 (0.60, 1.70) 
Number of PSA tests 
before biopsy 
    
    3 503 (30%) 163 (28%) 158 (31%) 178 (32%) 
    4 328 (20%) 123 (21%) 108 (21%) 96 (18%) 
    5 474 (29%) 160 (27%) 135 (26%) 174 (32%) 
    6 156 (9.4%) 62 (11%) 50 (10%) 44 (8.0%) 
    7 108 (6.5%) 36 (6.1%) 38 (7.5%) 34 (6.2%) 
    8 or more 85 5.1%) 42 (7.2%) 21 (4.1%) 22 (4.0%) 
*Includes 2 men who had both a BRCA1 and a BRCA2 mutation  
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Table 2. Models for any grade and high-grade cancers among men with any PSA measurement 
≥3.0ng/ml, N=116. All models were adjusted for age at biopsy and the last PSA measurement before 
biopsy. 
 Any grade cancer High grade cancer 
 OR 95% CI  p value OR 95% CI p value 
Age at biopsy 1.05 0.99, 1.12 0.13 1.08 0.99, 1.19 0.073 
Last PSA measurement before biopsy 1.05 0.89, 1.23 0.6 1.26 1.04, 1.52 0.017 
 
Age at biopsy 1.05 0.98, 1.12 0.14 1.09 0.99, 1.19 0.065 
Last PSA measurement before biopsy 1.08 0.89, 1.30 0.4 1.20 0.97, 1.49 0.10 
PSA velocity (arithmetic equation) 0.91 0.69, 1.21 0.5 1.20 0.81, 1.76 0.4 
 
Age at biopsy 1.06 0.99, 1.13 0.080 1.10 1.00, 1.20 0.047 
Last PSA measurement before biopsy 0.93 0.75, 1.17 0.5 1.12 0.88, 1.44 0.3 
PSA velocity (linear regression) 1.92 0.92, 4.00 0.080 2.07 0.93, 4.61 0.076 
 
Age at biopsy 1.06 0.99, 1.13 0.073 1.10 1.00, 1.21 0.042 
Last PSA measurement before biopsy 0.91 0.72, 1.16 0.4 1.09 0.83, 1.42 0.5 
PSA velocity (first and last value) 2.01 0.94, 4.29 0.073 2.25 0.96, 5.28 0.063 
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Table 3. Models for any grade and high grade cancers among all men undergoing biopsy, N=174. All 
models were adjusted for age at biopsy and the last PSA measurement before biopsy. 
 Any grade cancer High grade cancer 
 OR 95% CI p value OR 95% CI p value 
Age at biopsy 1.05 1.00, 1.11 0.051 1.08 1.00, 1.18 0.056 
Last PSA measurement before biopsy 1.13 1.00, 1.28 0.058 1.35 1.14, 1.59 0.001 
 
Age at biopsy 1.05 1.00, 1.10 0.064 1.09 1.00, 1.18 0.050 
Last PSA measurement before biopsy 1.17 1.01, 1.36 0.041 1.29 1.06, 1.57 0.010 
PSA velocity (arithmetic equation) 0.88 0.67, 1.17 0.4 1.19 0.79, 1.78 0.4 
 
Age at biopsy 1.06 1.00, 1.11 0.033 1.10 1.01, 1.19 0.036 
Last PSA measurement before biopsy 1.01 0.84, 1.22 0.9 1.19 0.95, 1.50 0.14 
PSA velocity (linear regression) 1.85 0.92, 3.71 0.085 2.09 0.95, 4.62 0.068 
 
Age at biopsy 1.06 1.01, 1.11 0.030 1.10 1.01, 1.20 0.033 
Last PSA measurement before biopsy 1.00 0.82, 1.22 >0.9 1.16 0.90, 1.49 0.2 
PSA velocity (first and last value) 1.90 0.93, 3.89 0.080 2.24 0.97, 5.20 0.059 
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Table 4. Models for any grade cancer based on BRCA status (BRCA positive carriers vs BRCA negative 
non-carriers) and BRCA2 status (BRCA2 positive vs BRCA1 positive and BRCA negative). All models 
were adjusted for age at biopsy, last PSA measurement before biopsy, BRCA status and the 
interaction between PSA or PSA velocity and BRCA status. 
 BRCA1 and BRCA2 vs BRCA 
non-carriers 
BRCA2 vs BRCA1 and BRCA 
non-carriers 
 OR 95% CI p value OR 95% CI p value 
Age at biopsy 1.07 1.01, 1.13 0.017 1.06 1.01, 1.12 0.022 
Last PSA measurement before biopsy 0.87 0.65, 1.16 0.3 0.99 0.81, 1.20 0.9 
BRCA1 or BRCA2 Positive 0.40 0.10, 1.67 0.2 0.74 0.21, 2.65 0.6 
Interaction between last PSA 
measurement and BRCA+ 
1.44 1.03, 2.02 0.031 1.28 0.97, 1.69 0.078 
       
Age at biopsy 1.06 1.00, 1.12 0.034 1.06 1.01, 1.12 0.025 
Last PSA measurement before biopsy 1.14 0.97, 1.35 0.10 1.06 0.89, 1.27 0.5 
PSA velocity using all PSAs (arithmetic 
equation) 
0.77 0.51, 1.16 0.2 0.72 0.49, 1.08 0.11 
BRCA1 or BRCA2 Positive 1.54 0.66, 3.61 0.3 1.07 0.43, 2.67 0.9 
Interaction between PSAV and BRCA+ 1.31 0.74, 2.34 0.4 2.63 1.13, 6.12 0.024 
       
Age at biopsy 1.07 1.01, 1.13 0.014 1.07 1.02, 1.13 0.010 
Last PSA measurement before biopsy 0.97 0.81, 1.18 0.8 0.93 0.75, 1.15 0.5 
PSA velocity using all PSAs (linear 
regression) 
1.19 0.49, 2.89 0.7 1.46 0.69, 3.11 0.3 
BRCA1 or BRCA2 Positive 0.99 0.37, 2.68 >0.9 0.93 0.34, 2.52 0.9 
Interaction between PSAV and BRCA+ 2.26 0.74, 6.90 0.2 3.26 1.01, 10.54 0.049 
       
Age at biopsy 1.07 1.01, 1.13 0.013 1.07 1.02, 1.13 0.009 
Last PSA measurement before biopsy 0.97 0.79, 1.18 0.7 0.92 0.74, 1.16 0.5 
PSA velocity using all PSAs (first and last 
value) 
1.24 0.50, 3.07 0.6 1.48 0.68, 3.18 0.3 
BRCA1 or BRCA2 Positive 1.01 0.37, 2.74 >0.9 0.92 0.34, 2.51 0.9 
Interaction between PSAV and BRCA+ 2.08 0.70, 6.20 0.2 2.96 0.97, 9.02 0.056 
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Table 5. Models for any grade cancer by BRCA2 status (BRCA2 carriers vs BRCA1 carriers and 
BRCA1/2 non-carriers). All models are adjusted for age at biopsy and last PSA measurement before 
biopsy. 
 BRCA2 Carriers(N=65) BRCA2 Non-carriers (N=109) 
 OR 95% CI p value OR 95% CI p 
value 
Age at biopsy 1.02 0.95, 1.10 0.6 1.10 1.02, 1.19 0.011 
Last PSA  
measurement before biopsy 
1.27 1.05, 1.54 0.013 0.97 0.79, 1.19 0.8 
       
Age at biopsy 1.03 0.95, 1.11 0.5 1.10 1.02, 1.19 0.017 
Last PSA  
measurement before biopsy 
1.12 0.81, 1.55 0.5 1.03 0.83, 1.27 0.8 
PSA velocity  
(arithmetic equation) 
1.61 0.57, 4.55 0.4 0.74 0.49, 1.11 0.14 
       
Age at biopsy 1.04 0.96, 1.12 0.4 1.11 1.02, 1.19 0.010 
Last PSA  
measurement before biopsy 
1.01 0.71, 1.44 >0.9 0.90 0.68, 1.19 0.4 
PSA velocity  
(linear regression) 
3.27 0.65, 16.38 0.15 1.56 0.66, 3.67 0.3 
       
Age at biopsy 1.04 0.96, 1.12 0.4 1.11 1.02, 1.19 0.010 
Last PSA  
measurement before biopsy 
1.00 0.67, 1.49 >0.9 0.89 0.67, 1.19 0.4 
PSA velocity  
(first and last value) 
3.08 0.58, 16.42 0.2 1.55 0.66, 3.66 0.3 
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